• Citer

Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial.

par Ignatiadis, M;Litière, Saskia;Rothe, F;Riethdorf, Sabine;Proudhon, Charlotte;Fehm, T;Aalders, Kim K.C.;Forstbauer, Helmut;Fasching, P A;Brain, E;Vuylsteke, P;Guardiola, E;Lorenz, R;Pantel, K;Tryfonidis, Konstantinos;Janni, Wolfgang;Piccart, M;Sotiriou, Christos ;Rack, B;Pierga, J-Y
Référence Annals of oncology, 29, 8, page (1777-1783)
Publication Publié, 2018-03-01

Article révisé par les pairs

• Détails
• Contenu

Résumé :

Trastuzumab improves the outcome of women with HER2 positive breast cancer. We aimed to assess whether trastuzumab decreases the detection rate of circulating tumor cells (CTCs) in women with high risk, HER2 nonamplified, early breast cancer.